Clinical trial results:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Tofacitinib (CP-690,550) in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least One TNF Inhibitor

Summary

EudraCT number	2013-001368-46
Trial protocol	CZ BE ES SK DE PL
Global end of trial date	04 April 2016

Results information

Result version number	v1 (current)
This version publication date	05 March 2017
First version publication date	05 March 2017

Trial information

Trial identification

Sponsor protocol code	A3921125

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01882439
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 May 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 April 2016
Global end of trial reached?	Yes
Global end of trial date	04 April 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objectives of this trial were to compare efficacy of tofacitinib at doses of 5 mg twice daily (BID) and 10 mg BID versus placebo for treatment of rheumatological signs and symptoms of active psoriatic arthritis (PsA) in subjects who have had an inadequate response in PsA to at least 1 tumor necrosis factor inhibitor (TNFi); to compare physical function status after administration of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo in subjects with active PsA who have had an inadequate response in PsA to at least 1 TNFi; and to compare the safety and tolerability of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo in subjects with active PsA who have had an inadequate response in PsA to at least 1 TNFi.

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation Good Clinical Practice Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial participants. The final protocol and any amendments were reviewed and approved by the Institutional Review Board(s) and/or Independent Ethics Committee(s) at each of the investigational centres participating in the study.

Background therapy:

During the study, participants remained on a stable dose of 1 conventional synthetic (or non-biologic) Disease-Modifying Anti-Rheumatic Drug, eg, methotrexate, sulfasalazine, leflunomide, or other drug as approved by the Pfizer Study Clinician.

Evidence for comparator: -

Actual start date of recruitment	22 August 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 16
Country: Number of subjects enrolled	Belgium: 17
Country: Number of subjects enrolled	Brazil: 11
Country: Number of subjects enrolled	Czech Republic: 2
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Germany: 40
Country: Number of subjects enrolled	Mexico: 45
Country: Number of subjects enrolled	Poland: 54
Country: Number of subjects enrolled	Russian Federation: 31
Country: Number of subjects enrolled	Slovakia: 2
Country: Number of subjects enrolled	Spain: 23

Country: Number of subjects enrolled	Taiwan: 9
Country: Number of subjects enrolled	United Kingdom: 24
Country: Number of subjects enrolled	United States: 118
Worldwide total number of subjects	394
EEA total number of subjects	164

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	355
From 65 to 84 years	39
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Data through End of Study (Month 6)

Pre-assignment

Screening details:

Of 546 participants screened for entry into the study, 395 were enrolled and randomized, 394 received treatment.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Tofacitinib, 5 mg twice daily

Arm description:

Participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet twice daily.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	CP-690,550
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Tofacitinib 5 mg administered twice daily, with one placebo tablet administered twice daily.

Arm title	Tofacitinib, 10 mg, twice daily

Arm description:

Participants received two 5 mg tofacitinib tablets, twice daily.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	CP-690,550
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Two 5 mg tofacitinib tablets administered twice daily

Arm title	Placebo/Tofacitinib, 5 mg, twice daily

Arm description:

Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet, twice daily.

Arm type	Experimental

Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	CP-690,550
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Two placebo tablets administered twice daily, up to 3 months. At the end of this period, one 5 mg tofacitinib tablet administered twice daily, and one placebo tablet administered twice daily.

Arm title	Placebo/Tofacitinib, 10 mg, twice daily

Arm description:

Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received two 5 mg tofacitinib tablets, twice daily.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	CP-690,550
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Two placebo tablets administered twice daily, up to 3 months. At the end of this period, two 5 mg tofacitinib tablets administered twice daily.

Number of subjects in period 1	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily
Started	131	132	66
Completed	122	111	56
Not completed	9	21	10
Pregnancy	-	1	-
No longer willing to participate	1	4	2
Adverse event unrelated to study drug	2	2	1
Medication error with no associated AE	-	-	2
Adverse event related to study drug	3	8	1
Protocol deviation	2	2	-
Insufficient clinical response	1	4	4

Number of subjects in period 1	Placebo/Tofacitinib, 10 mg, twice daily
Started	65
Completed	56
Not completed	9
Pregnancy	-
No longer willing to participate	3
Adverse event unrelated to study drug	1
Medication error with no associated AE	-
Adverse event related to study drug	2

Protocol deviation	1
Insufficient clinical response	2

Baseline characteristics

Reporting groups	
Reporting group title	Tofacitinib, 5 mg twice daily
Reporting group description:	
Participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet twice daily.	
Reporting group title	Tofacitinib, 10 mg, twice daily
Reporting group description:	
Participants received two 5 mg tofacitinib tablets, twice daily.	
Reporting group title	Placebo/Tofacitinib, 5 mg, twice daily
Reporting group description:	
Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet, twice daily.	
Reporting group title	Placebo/Tofacitinib, 10 mg, twice daily
Reporting group description:	
Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received two 5 mg tofacitinib tablets, twice daily.	

Reporting group values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily
Number of subjects	131	132	66
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	119	119	61
From 65-84 years	12	13	5
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	49.5	51.3	48.7
standard deviation	± 12.3	± 10.9	± 11.2
Gender, Male/Female			
Units: Subjects			
Female	64	74	38
Male	67	58	28

Reporting group values	Placebo/Tofacitinib, 10 mg, twice daily	Total	
Number of subjects	65	394	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	

Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	56	355	
From 65-84 years	9	39	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	49.3		
standard deviation	± 14	-	
Gender, Male/Female			
Units: Subjects			
Female	42	218	
Male	23	176	

End points

End points reporting groups

Reporting group title	Tofacitinib, 5 mg twice daily

Reporting group description:

Participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet twice daily.

Reporting group title	Tofacitinib, 10 mg, twice daily

Reporting group description:

Participants received two 5 mg tofacitinib tablets, twice daily.

Reporting group title	Placebo/Tofacitinib, 5 mg, twice daily

Reporting group description:

Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet, twice daily.

Reporting group title	Placebo/Tofacitinib, 10 mg, twice daily

Reporting group description:

Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received two 5 mg tofacitinib tablets, twice daily.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Subject analysis set title	Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received two placebo tablets twice daily up to 3 months.

Primary: Percentage of Participants Meeting American College of Rheumatology Response Criteria greater than or equal to (≥) 20% (ACR20): Month 3

End point title	Percentage of Participants Meeting American College of Rheumatology Response Criteria greater than or equal to (≥) 20% (ACR20): Month 3 [1]

End point description:

ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-reactive protein (CRP).

End point type	Primary

End point timeframe:

Month 3

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	131	132	131	
Units: Percentage of participants				
number (not applicable)	49.62	46.97	23.66	

Statistical analyses

Statistical analysis title	Analysis of ACR20
Comparison groups	Tofacitinib, 5 mg twice daily v Placebo
Number of subjects included in analysis	262
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Large sample approximation
Parameter estimate	Risk difference (RD)
Point estimate	25.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.72
upper limit	37.19
Variability estimate	Standard error of the mean
Dispersion value	5.73

Statistical analysis title	Analysis of ACR20

Comparison groups	Tofacitinib, 10 mg, twice daily v Placebo
Number of subjects included in analysis	263
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Large sample approximation
Parameter estimate	Risk difference (RD)
Point estimate	23.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.1
upper limit	34.51
Variability estimate	Standard error of the mean
Dispersion value	5.71

Primary: Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3

End point title	Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3[2]

End point description:

The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.

End point type	Primary

End point timeframe:

Month 3

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	129	132	131	
Units: Units on a scale				
least squares mean (standard error)	-0.392 (± 0.04544)	-0.354 (± 0.04579)	-0.1391 (± 0.04573)	

Statistical analyses

Statistical analysis title	Analysis of HAQ-DI
Comparison groups	Tofacitinib, 5 mg twice daily v Placebo

Number of subjects included in analysis	260
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Mean difference (net)
Point estimate	-0.2529
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3792
upper limit	-0.1266
Variability estimate	Standard error of the mean
Dispersion value	0.06422

Statistical analysis title	Analysis of HAQ-DI
Comparison groups	Tofacitinib, 10 mg, twice daily v Placebo
Number of subjects included in analysis	263
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0009
Method	Mixed models analysis
Parameter estimate	Mean difference (net)
Point estimate	-0.215
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3419
upper limit	-0.0881
Variability estimate	Standard error of the mean
Dispersion value	0.06453

Secondary: Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6

End point title	Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6

End point description:

ACR50 was calculated as a ≥50% improvement from baseline in tender /painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Week 2 and Months 1, 2, 3, 4, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	132	66	65
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=8,13,NA,NA,4)	6.11	9.85	9999	9999
Month 1 (n=23,14,NA,NA,8)	17.56	10.61	9999	9999
Month 2 (n=33,30,NA,NA,14)	25.19	22.73	9999	9999
Month 3 (n=39,37,NA,NA,19)	29.77	28.03	9999	9999
Month 4 (n=50,38,15,21,NA)	38.17	28.79	22.73	32.31
Month 6 (n=50,39,21,23,NA)	38.17	29.55	31.82	35.38

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	131			
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=8,13,NA,NA,4)	3.05			
Month 1 (n=23,14,NA,NA,8)	6.11			
Month 2 (n=33,30,NA,NA,14)	10.69			
Month 3 (n=39,37,NA,NA,19)	14.5			
Month 4 (n=50,38,15,21,NA)	9999			
Month 6 (n=50,39,21,23,NA)	9999			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6

End point title	Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6

End point description:

ACR70 was calculated as a ≥70% improvement from baseline in tender /painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Week 2 and Months 1, 2, 3, 4, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	132	66	65
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=2,3,NA,NA,1)	1.53	2.27	9999	9999
Month 1 (n=7,5,NA,NA,3)	5.34	3.79	9999	9999
Month 2 (n=17,13,NA,NA,6)	12.98	9.85	9999	9999
Month 3 (n=22,19,NA,NA,13)	16.79	14.39	9999	9999
Month 4 (n=24,20,6,14,NA)	18.32	15.15	9.09	21.54
Month 6 (n=28,19,10,12,NA)	21.37	14.39	15.15	18.46

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	131			
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=2,3,NA,NA,1)	0.76			
Month 1 (n=7,5,NA,NA,3)	2.29			
Month 2 (n=17,13,NA,NA,6)	4.58			
Month 3 (n=22,19,NA,NA,13)	9.92			
Month 4 (n=24,20,6,14,NA)	9999			
Month 6 (n=28,19,10,12,NA)	9999			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Meeting American College of Rheumatology Response Criteria greater than or equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6

End point title	Percentage of Participants Meeting American College of Rheumatology Response Criteria greater than or equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6

End point description:

ACR20 was calculated as a ≥20% improvement from baseline in tender /painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Week 2 and Months 1, 2, 4, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	132	66	65
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=35,38,NA,NA,17)	26.72	28.79	9999	9999
Month 1 (n=45,56,NA,NA,29)	34.35	42.42	9999	9999
Month 2 (n=63,63,NA,NA,34)	48.09	47.73	9999	9999
Month 4 (n=78,69,30,33,NA)	59.54	52.27	45.45	50.77
Month 6 (n=78,65,33,35,NA)	59.54	49.24	50	53.85

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	131			
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=35,38,NA,NA,17)	12.98			
Month 1 (n=45,56,NA,NA,29)	22.14			
Month 2 (n=63,63,NA,NA,34)	25.95			
Month 4 (n=78,69,30,33,NA)	9999			
Month 6 (n=78,65,33,35,NA)	9999			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6

End point title	Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6

End point description:

The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. n=number of evaluable participants, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Week 2 and Months 1, 2, 4, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	129	132	66	65
Units: Units on scale				
least squares mean (standard error)				
Week 2 (n=129,130,NA,NA,128)	-0.2198 (± 0.03145)	-0.1652 (± 0.0316)	9999 (± 9999)	9999 (± 9999)
Month 1 (n=128,129,NA,NA,130)	-0.3229 (± 0.04074)	-0.2279 (± 0.04073)	9999 (± 9999)	9999 (± 9999)
Month 2 (n=125,126,NA,NA,121)	-0.4114 (± 0.04311)	-0.3131 (± 0.04316)	9999 (± 9999)	9999 (± 9999)
Month 4 (n=125,121,57,58,NA)	-0.4455 (± 0.04489)	-0.3305 (± 0.04523)	-0.3836 (± 0.06443)	-0.3918 (± 0.06418)
Month 6 (n=122,112,56,56,NA)	-0.4365 (± 0.04642)	-0.3397 (± 0.0472)	-0.4808 (± 0.0668)	-0.4157 (± 0.06665)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	131			
Units: Units on scale				
least squares mean (standard error)				
Week 2 (n=129,130,NA,NA,128)	-0.0655 (± 0.03133)			
Month 1 (n=128,129,NA,NA,130)	-0.1481 (± 0.04038)			
Month 2 (n=125,126,NA,NA,121)	-0.162 (± 0.04317)			
Month 4 (n=125,121,57,58,NA)	9999 (± 9999)			
Month 6 (n=122,112,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3

End point title	Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3[3]

End point description:

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

End point type	Secondary

End point timeframe:

Month 3

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	130	132	131	
Units: mg/L				
least squares mean (standard error)	-5.4657 (± 1.80096)	-5.9156 (± 1.83181)	1.0233 (± 1.82879)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3

End point title	Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3[4]

End point description:

Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

End point type	Secondary

End point timeframe:

Month 3

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	129	132	131	
Units: mm				
least squares mean (standard error)	-21.66 (± 2.162)	-20.88 (± 2.188)	-7.72 (± 2.184)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3

End point title	Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3[5]

End point description:

Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS.

End point type	Secondary

End point timeframe:

Month 3

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	129	132	131	
Units: mm				
least squares mean (standard error)	-21.59 (± 2.228)	-19.88 (± 2.248)	-7.14 (± 2.247)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3

End point title	Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3[6]

End point description:

The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS.

End point type	Secondary

End point timeframe:

Month 3

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	128	130	128	
Units: mm				
least squares mean (standard error)	-27.25 (± 1.893)	-28.95 (± 1.916)	-15.88 (± 1.929)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3

End point title	Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3 [7]

End point description:

Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

End point type	Secondary

End point timeframe:

Month 3

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	130	132	131	
Units: Joints				
least squares mean (standard error)	-7.6 (± 0.59)	-6.7 (± 0.6)	-2.7 (± 0.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3

End point title	Change from Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3 [8]

End point description:

Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

End point type	Secondary

End point timeframe:

Month 3

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Since participants received only Placebo up to 3 months in the 'Placebo/Tofacitinib, 5 mg, twice daily' and 'Placebo/Tofacitinib, 10 mg, twice daily' treatment groups, data up to and including 3 months are combined into one 'Placebo' subject analysis set.

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	130	132	131	
Units: Joints				
least squares mean (standard error)	-9.9 (± 0.97)	-9.7 (± 0.98)	-4.5 (± 0.98)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6

End point title	Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6

End point description:

The PsARC covers 4 measures: Tender joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count. n=number of responders, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Week 2, Months 1, 2, 3, 4, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	132	66	65
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=43,45,NA,NA,23)	32.82	34.09	9999	9999
Month 1 (n=56,66,NA,NA,45)	42.75	50	9999	9999
Month 2 (n=67,72,NA,NA,43)	51.15	54.55	9999	9999
Month 3 (n=77,64,NA,NA,38)	58.78	48.48	9999	9999
Month 4 (n=74,75,34,38.NA)	56.49	56.82	51.52	58.46
Month 6 (n=77,68,34,36,NA)	58.78	51.52	51.52	55.38

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	131			
Units: Percentage of participants				
number (not applicable)				
Week 2 (n=43,45,NA,NA,23)	17.56			
Month 1 (n=56,66,NA,NA,45)	34.35			
Month 2 (n=67,72,NA,NA,43)	32.82			
Month 3 (n=77,64,NA,NA,38)	29.01			
Month 4 (n=74,75,34,38.NA)	9999			
Month 6 (n=77,68,34,36,NA)	9999			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) response: Months 1, 3, and 6

End point title	Change from Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) response: Months 1, 3, and 6

End point description:

The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO. Analysis: all participants who were randomized, received at least 1 dose of study drug with baseline PGA-PsO >0, and were evaluable. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121	124	63	62
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=120,122,NA,NA,125)	-0.5 (± 0.07)	-0.8 (± 0.07)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=112,116,NA,NA,112)	-0.7 (± 0.08)	-1.1 (± 0.08)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=116,108,55,51,NA)	-0.9 (± 0.08)	-1.1 (± 0.09)	-1 (± 0.12)	-1 (± 0.13)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	125			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=120,122,NA,NA,125)	-0.2 (± 0.07)			
Month 3 (n=112,116,NA,NA,112)	-0.4 (± 0.08)			
Month 6 (n=116,108,55,51,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6

End point title	Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6

End point description:

PASI determines psoriasis severity based on lesion severity & % of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration & scaling; each evaluated separately for head & neck, upper limbs, trunk & lower limbs then rated for each body area on a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis & is given a numerical score. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 defined as 75% reduction from baseline in PASI. Analysis: all participants with PASI >0 and BSA ≥3% at baseline. n=number of responders, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	80	81	42	44
Units: Percentage of participants				
number (not applicable)				
Month 1 (n=12,15,NA,NA,5)	15	18.52	9999	9999
Month 3 (n=17,35,NA,NA,12)	21.25	43.21	9999	9999
Month 6 (n=27,37,11,14,NA)	33.75	45.68	26.19	31.82

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	86			
Units: Percentage of participants				

number (not applicable)				
Month 1 (n=12,15,NA,NA,5)	5.81			
Month 3 (n=17,35,NA,NA,12)	13.95			
Month 6 (n=27,37,11,14,NA)	9999			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6

End point title	Change from Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6

End point description:

Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness. Analysis population: all participants who were randomized, received at least 1 dose of study drug with baseline DSS >0, and were evaluable. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	64	29	33
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=65,64,NA,NA,62)	-2.8 (± 0.63)	-4 (± 0.65)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=64,58,NA,NA,55)	-5.2 (± 0.73)	-5.4 (± 0.78)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=61,55,25,26,NA)	-6 (± 0.84)	-6 (± 0.9)	-5.4 (± 1.33)	-5.2 (± 1.26)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=65,64,NA,NA,62)	-1.1 (± 0.64)			
Month 3 (n=64,58,NA,NA,55)	-1.9 (± 0.78)			
Month 6 (n=61,55,25,26,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6

End point title	Change from Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6

End point description:

The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. Analysis population: All participants who were randomized, received at least 1 dose of study drug with baseline SPARCC Enthesitis Index >0, and were evaluable. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	95	105	47	51
Units: Units of scale				
least squares mean (standard error)				
Month 1 (n=94,104,NA,NA,98)	-1.9 (± 0.31)	-1.9 (± 0.3)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=92,96,NA,NA,87)	-2.5 (± 0.34)	-2.8 (± 0.33)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=91,93,40,43,NA)	-2.6 (± 0.36)	-3.1 (± 0.35)	-2.6 (± 0.53)	-2.4 (± 0.51)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	98			
Units: Units of scale				
least squares mean (standard error)				
Month 1 (n=94,104,NA,NA,98)	-1 (± 0.3)			
Month 3 (n=92,96,NA,NA,87)	-1.3 (± 0.34)			
Month 6 (n=91,93,40,43,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6

End point title	Change from Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6

End point description:

Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0-6. Higher score indicates greater severity of enthesitis. Analysis population: all participants who were randomized, received at least 1 dose of study drug with baseline LEI >0, and were evaluable. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, and 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	82	96	45	46
Units: Units of scale				
least squares mean (standard error)				
Month 1 (n=82,95,NA,NA,91)	-1 (± 0.19)	-0.8 (± 0.18)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=79,86,NA,NA,82)	-1.3 (± 0.19)	-1.3 (± 0.18)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=77,84,38,41,NA)	-1.5 (± 0.19)	-1.6 (± 0.18)	-1.4 (± 0.26)	-1.3 (± 0.26)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	91			
Units: Units of scale				
least squares mean (standard error)				
Month 1 (n=82,95,NA,NA,91)	-0.5 (± 0.18)			
Month 3 (n=79,86,NA,NA,82)	-0.5 (± 0.19)			
Month 6 (n=77,84,38,41,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Physical Component Summary Score: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Physical Component Summary Score: Months 1, 3, 6

End point description:

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary score and the mental component summary score. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	124	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=124,127,NA,NA,129)	4.65 (± 0.543)	3.98 (± 0.542)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=121,120,NA,NA,117)	5.18 (± 0.684)	5.34 (± 0.687)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=118,110,56,56,NA)	5.71 (± 0.751)	5 (± 0.768)	6.45 (± 1.076)	6.98 (± 1.074)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=124,127,NA,NA,129)	1.7 (± 0.534)			
Month 3 (n=121,120,NA,NA,117)	1.77 (± 0.689)			
Month 6 (n=118,110,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Mental Component Summary Score: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey

	Version 2, Acute (SF-36v2 acute): Mental Component Summary Score: Months 1, 3, 6

End point description:

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary score and the mental component summary score. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	124	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=124,127,NA,NA,129)	4.09 (± 0.74)	4.19 (± 0.738)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=121,120,NA,NA,117)	4.94 (± 0.875)	4.28 (± 0.879)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=118,110,56,56,NA)	5.36 (± 0.878)	5.37 (± 0.902)	5.37 (± 1.265)	6.47 (± 1.259)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=124,127,NA,NA,129)	2.33 (± 0.725)			
Month 3 (n=121,120,NA,NA,117)	2.97 (± 0.88)			
Month 6 (n=118,110,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Physical functioning Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Physical functioning Domain: Months 1, 3, 6

End point description:

The 10 items of the physical functioning scale represent levels and kinds of limitations between the extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture both the presence and extent of physical limitations using a 3-level response continuum. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary
End point timeframe: Months 1, 3, 6	

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	3.97 (± 0.583)	3.1 (± 0.587)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	5 (± 0.721)	4.08 (± 0.732)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=121,112,56,56,NA)	5.39 (± 0.795)	3.88 (± 0.818)	5.89 (± 1.153)	5.6 (± 1.149)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	1.55 (± 0.58)			
Month 3 (n=124,120,NA,NA,117)	1.69 (± 0.734)			
Month 6 (n=121,112,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Role-physical Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Role-physical Domain: Months 1, 3, 6

End point description:

The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role-physical scale are answered on a 5-point scale. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary
End point timeframe: Months 1, 3, 6	

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	126	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=126,128,NA,NA,129)	4.22 (± 0.63)	3.55 (± 0.633)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=122,120,NA,NA,117)	4.99 (± 0.805)	5.44 (± 0.814)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=120,112,56,56,NA)	5.58 (± 0.857)	5.24 (± 0.881)	7.01 (± 1.241)	7.21 (± 1.239)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=126,128,NA,NA,129)	2.24 (± 0.623)			
Month 3 (n=122,120,NA,NA,117)	2.85 (± 0.814)			
Month 6 (n=120,112,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Bodily Pain Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Bodily Pain Domain: Months 1, 3, 6

End point description:

The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	127	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=127,128,NA,NA,129)	6.86 (± 0.634)	6.39 (± 0.638)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	7 (± 0.786)	7.59 (± 0.799)	9999 (± 9999)	9999 (± 9999)

Month 6 (n=121,112,56,56,NA)	7.6 (± 0.848)	7.69 (± 0.876)	8.15 (± 1.234)	10.48 (± 1.236)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=127,128,NA,NA,129)	2.31 (± 0.633)			
Month 3 (n=124,120,NA,NA,117)	2.1 (± 0.804)			
Month 6 (n=121,112,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): General Health Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): General Health Domain: Months 1, 3, 6

End point description:

The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	3.24 (± 0.529)	3.74 (± 0.535)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	3.67 (± 0.639)	3.92 (± 0.651)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=121,111,56,56,NA)	3.88 (± 0.695)	4.46 (± 0.719)	6 (± 1.01)	5.34 (± 1.01)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			

Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	2.29 (± 0.527)			
Month 3 (n=124,120,NA,NA,117)	2.45 (± 0.651)			
Month 6 (n=121,111,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Vitality Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Vitality Domain: Months 1, 3, 6

End point description:

This 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	4.52 (± 0.678)	4.3 (± 0.684)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	4.95 (± 0.828)	4.75 (± 0.842)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,111,56,56,NA)	5.94 (± 0.859)	5.15 (± 0.894)	5.75 (± 1.256)	7.06 (± 1.256)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	1.73 (± 0.674)			
Month 3 (n=124,120,NA,NA,117)	2.41 (± 0.843)			
Month 6 (n=122,111,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Social Functioning Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Social Functioning Domain: Months 1, 3, 6

End point description:

This 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	4.93 (± 0.748)	4.92 (± 0.754)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	6.25 (± 0.844)	5.46 (± 0.861)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,112,56,56,NA)	5.92 (± 0.896)	5.58 (± 0.93)	5.96 (± 1.309)	7.9 (± 1.305)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	2.33 (± 0.744)			
Month 3 (n=124,120,NA,NA,117)	2.89 (± 0.861)			
Month 6 (n=122,112,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Role-emotional Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Role-emotional Domain: Months 1, 3, 6

End point description:

The 3-item role-emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	125	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=125,128,NA,NA,129)	4.44 (± 0.894)	3.64 (± 0.892)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=121,120,NA,NA,117)	5.44 (± 0.998)	4.84 (± 1.003)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=119,111,56,56,NA)	6.17 (± 1.01)	5.69 (± 1.04)	7.05 (± 1.461)	8 (± 1.455)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=125,128,NA,NA,129)	3.25 (± 0.878)			
Month 3 (n=121,120,NA,NA,117)	3.85 (± 1.002)			
Month 6 (n=119,111,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Mental Health Domain: Months 1, 3, 6

End point title	Change from Baseline in the Short-Form-36 Health Survey Version 2, Acute (SF-36v2 acute): Mental Health Domain: Months 1, 3, 6

End point description:

The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	3.8 (± 0.737)	4.41 (± 0.743)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	4.36 (± 0.852)	4.11 (± 0.867)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,112,56,56,NA)	4.38 (± 0.854)	4.98 (± 0.884)	5.06 (± 1.245)	5.67 (± 1.241)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	1.73 (± 0.732)			
Month 3 (n=124,120,NA,NA,117)	2.11 (± 0.868)			
Month 6 (n=122,112,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6

End point title	Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6

End point description:

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual’s rating for their current health-related quality of life state. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.15 (± 0.035)	-0.1 (± 0.036)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	-0.17 (± 0.038)	-0.15 (± 0.039)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,112,56,55,NA)	-0.15 (± 0.04)	-0.15 (± 0.042)	-0.23 (± 0.059)	-0.32 (± 0.059)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.08 (± 0.035)			
Month 3 (n=124,120,NA,NA,117)	-0.05 (± 0.039)			
Month 6 (n=122,112,56,55,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6

End point title	Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6

End point description:

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	127	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=127,128,NA,NA,129)	-0.11 (± 0.039)	-0.14 (± 0.039)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=122,120,NA,NA,117)	-0.15 (± 0.039)	-0.15 (± 0.04)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=120,112,56,55,NA)	-0.19 (± 0.04)	-0.15 (± 0.042)	-0.19 (± 0.058)	-0.17 (± 0.059)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=127,128,NA,NA,129)	-0.03 (± 0.038)			
Month 3 (n=122,120,NA,NA,117)	-0.04 (± 0.039)			
Month 6 (n=120,112,56,55,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6

End point title	Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6

End point description:

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.22 (± 0.039)	-0.19 (± 0.039)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	-0.23 (± 0.042)	-0.22 (± 0.042)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,112,56,55,NA)	-0.3 (± 0.047)	-0.25 (± 0.048)	-0.39 (± 0.068)	-0.34 (± 0.068)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.17 (± 0.039)			
Month 3 (n=124,120,NA,NA,117)	-0.15 (± 0.043)			
Month 6 (n=122,112,56,55,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6

End point title	Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6

End point description:

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.26 (± 0.038)	-0.25 (± 0.039)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	-0.32 (± 0.043)	-0.29 (± 0.044)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=121,112,56,55,NA)	-0.34 (± 0.045)	-0.31 (± 0.047)	-0.42 (± 0.066)	-0.34 (± 0.067)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.11 (± 0.038)			
Month 3 (n=124,120,NA,NA,117)	-0.12 (± 0.044)			
Month 6 (n=121,112,56,55,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6

End point title	Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6

End point description:

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.13 (± 0.043)	-0.21 (± 0.043)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	-0.19 (± 0.044)	-0.2 (± 0.045)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,112,56,55,NA)	-0.16 (± 0.046)	-0.2 (± 0.048)	-0.17 (± 0.068)	-0.31 (± 0.068)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,128,NA,NA,129)	-0.1 (± 0.042)			
Month 3 (n=124,120,NA,NA,117)	-0.12 (± 0.045)			
Month 6 (n=122,112,56,55,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6

End point title	Change from Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6

End point description:

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual’s rating for their current health-related quality of life state. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: mm				
least squares mean (standard error)				
Month 1 (n=127,128,NA,NA,128)	9.76 (± 1.565)	9.58 (± 1.574)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,119,NA,NA,117)	8.62 (± 1.853)	12.33 (± 1.896)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,112,56,55,NA)	12.14 (± 1.87)	12.63 (± 1.945)	15.68 (± 2.736)	15.32 (± 2.748)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: mm				
least squares mean (standard error)				
Month 1 (n=127,128,NA,NA,128)	3.59 (± 1.557)			
Month 3 (n=124,119,NA,NA,117)	2.64 (± 1.896)			
Month 6 (n=122,112,56,55,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6

End point title	Change from Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6

End point description:

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (“washed out”), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	6 (± 0.66)	4.4 (± 0.67)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	7 (± 0.81)	5.8 (± 0.82)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,113,56,56,NA)	7.1 (± 0.87)	6.2 (± 0.9)	7.6 (± 1.28)	8.5 (± 1.28)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	2.2 (± 0.66)			
Month 3 (n=124,120,NA,NA,117)	3 (± 0.82)			
Month 6 (n=122,113,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6

End point title	Change from Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6

End point description:

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	2.7 (± 0.31)	2.3 (± 0.31)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	3.1 (± 0.38)	2.6 (± 0.39)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,113,56,56,NA)	2.9 (± 0.4)	2.8 (± 0.41)	3.2 (± 0.58)	4.1 (± 0.58)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	1 (± 0.3)			
Month 3 (n=124,120,NA,NA,117)	1.5 (± 0.39)			
Month 6 (n=122,113,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6

End point title	Change from Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6

End point description:

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (“washed out”), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	128	130	64	65
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	3.3 (± 0.4)	2.1 (± 0.41)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=124,120,NA,NA,117)	3.9 (± 0.48)	3.2 (± 0.49)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=122,113,56,56,NA)	4.2 (± 0.52)	3.5 (± 0.54)	4.3 (± 0.76)	4.5 (± 0.76)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	129			
Units: Units on a scale				
least squares mean (standard error)				
Month 1 (n=128,129,NA,NA,129)	1.2 (± 0.4)			
Month 3 (n=124,120,NA,NA,117)	1.6 (± 0.49)			
Month 6 (n=122,113,56,56,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6

End point title	Change from Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6

End point description:

BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participants answered 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averaged the individual assessments for a final score ranging 0-10. Analysis population: all participants who were randomized, received at least 1 dose of study drug with presence of spondylitis at screening and baseline BASDAI score >0 cm, and were evaluable. n=number of participants evaluable, NA=not applicable, 9999=results not reported for this group.

End point type	Secondary

End point timeframe:

Months 1, 3, 6

End point values	Tofacitinib, 5 mg twice daily	Tofacitinib, 10 mg, twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	25	10	12
Units: cm				
least squares mean (standard error)				
Month 1 (n=26,25,NA,NA,22)	-2.04 (± 0.4)	-1.26 (± 0.412)	9999 (± 9999)	9999 (± 9999)
Month 3 (n=26,22,NA,NA,19)	-2.26 (± 0.465)	-1.92 (± 0.49)	9999 (± 9999)	9999 (± 9999)
Month 6 (n=25,22,8,10,NA)	-2.02 (± 0.463)	-1.56 (± 0.489)	-2.26 (± 0.756)	-3.05 (± 0.701)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	22			
Units: cm				
least squares mean (standard error)				
Month 1 (n=26,25,NA,NA,22)	-0.34 (± 0.415)			
Month 3 (n=26,22,NA,NA,19)	-1 (± 0.506)			
Month 6 (n=25,22,8,10,NA)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events (AEs) were assessed from first administration of study treatment through last visit. Serious AEs (SAEs) were assessed from informed consent through and including 28 calendar days after last administration of investigational product.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.0

Reporting groups

Reporting group title	Tofacitinib, 5 mg twice daily

Reporting group description:

Participants received one 5 mg tofacitinib tablet twice daily and one placebo tablet twice daily.

Reporting group title	Placebo/Tofacitinib, 5 mg, twice daily

Reporting group description:

Participants received two placebo tablets twice daily up to 3 months. At the end of this period, participants received one 5 mg tofacitinib tablet twice daily and one placebo tablet twice daily.

Reporting group title	Placebo/Tofacitinib, 10 mg, twice daily

Reporting group description:

Participants received two placebo tablets twice daily up to 3 months. At the end of this period, participants received two 5 mg tofacitinib tablets twice daily.

Reporting group title	Tofacitinib, 10 mg, twice daily

Reporting group description:

Participants received two 5 mg tofacitinib tablets twice daily.

Serious adverse events	Tofacitinib, 5 mg twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 131 (3.82%)	2 / 66 (3.03%)	1 / 65 (1.54%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

Hypertensive crisis			
subjects affected / exposed	0 / 131 (0.00%)	1 / 66 (1.52%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 131 (0.76%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 131 (0.76%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	1 / 131 (0.76%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 131 (0.00%)	1 / 66 (1.52%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Inguinal hernia			

subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 131 (0.00%)	1 / 66 (1.52%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscle haemorrhage			
subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Oral candidiasis			
subjects affected / exposed	1 / 131 (0.76%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parotitis			
subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 131 (0.76%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	0 / 131 (0.00%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 131 (0.76%)	0 / 66 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Tofacitinib, 10 mg, twice daily		
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 132 (6.06%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tibia fracture			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertensive crisis			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			

subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angina pectoris			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial flutter			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Inguinal hernia			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Hyperthyroidism			

subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Muscle haemorrhage			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Oral candidiasis			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Parotitis			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 132 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Tofacitinib, 5 mg twice daily	Placebo/Tofacitinib, 5 mg, twice daily	Placebo/Tofacitinib, 10 mg, twice daily
Total subjects affected by non-serious adverse events			
subjects affected / exposed	49 / 131 (37.40%)	19 / 66 (28.79%)	19 / 65 (29.23%)
Vascular disorders			
Hypertension			
subjects affected / exposed	8 / 131 (6.11%)	2 / 66 (3.03%)	2 / 65 (3.08%)
occurrences (all)	8	2	2
Nervous system disorders			
Dizziness			
subjects affected / exposed	7 / 131 (5.34%)	0 / 66 (0.00%)	1 / 65 (1.54%)
occurrences (all)	8	0	1
Headache			
subjects affected / exposed	10 / 131 (7.63%)	3 / 66 (4.55%)	4 / 65 (6.15%)
occurrences (all)	11	3	5
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	10 / 131 (7.63%)	2 / 66 (3.03%)	2 / 65 (3.08%)
occurrences (all)	10	2	2
Nausea			
subjects affected / exposed	5 / 131 (3.82%)	5 / 66 (7.58%)	4 / 65 (6.15%)
occurrences (all)	5	5	4
Infections and infestations			
Bronchitis			
subjects affected / exposed	3 / 131 (2.29%)	1 / 66 (1.52%)	2 / 65 (3.08%)
occurrences (all)	3	1	2
Nasopharyngitis			
subjects affected / exposed	14 / 131 (10.69%)	4 / 66 (6.06%)	1 / 65 (1.54%)
occurrences (all)	18	8	1
Sinusitis			
subjects affected / exposed	3 / 131 (2.29%)	4 / 66 (6.06%)	2 / 65 (3.08%)
occurrences (all)	3	4	2
Upper respiratory tract infection			
subjects affected / exposed	12 / 131 (9.16%)	4 / 66 (6.06%)	7 / 65 (10.77%)
occurrences (all)	14	4	7

Non-serious adverse events	Tofacitinib, 10 mg, twice daily		
Total subjects affected by non-serious adverse events			

subjects affected / exposed	48 / 132 (36.36%)		
Vascular disorders			
Hypertension			
subjects affected / exposed	5 / 132 (3.79%)		
occurrences (all)	5		
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 132 (0.76%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	12 / 132 (9.09%)		
occurrences (all)	13		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	8 / 132 (6.06%)		
occurrences (all)	8		
Nausea			
subjects affected / exposed	7 / 132 (5.30%)		
occurrences (all)	7		
Infections and infestations			
Bronchitis			
subjects affected / exposed	7 / 132 (5.30%)		
occurrences (all)	7		
Nasopharyngitis			
subjects affected / exposed	12 / 132 (9.09%)		
occurrences (all)	16		
Sinusitis			
subjects affected / exposed	5 / 132 (3.79%)		
occurrences (all)	5		
Upper respiratory tract infection			
subjects affected / exposed	7 / 132 (5.30%)		
occurrences (all)	7		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 May 2013	Included country specific requirement for participants in Taiwan to be ≥20 years of age for inclusion; increased absolute lymphocyte count to <1.0 × 10^9/L (<1000 mm^3) as exclusion criterion per regulatory feedback; replaced "target plaque lesion" with "site of enthesitis" for photography; added "Opportunistic Infections" as a criteria for participant discontinuation; updated Safety Event Review text; clarified need for radiologist or pulmonologist to read chest radiograph per local standard of care; in Czech Republic, included need for pulmonologist to review TB tests.
13 December 2013	Updated Introduction to reflect revised Investigator's Brochure; included certolizumab minimum treatment duration and washout information since recent marketing approval for PsA; standardized text for washout period for other biologic agents per regulatory request; added 'localized' infection to exclusion criteria #15 and added new exclusion criterion (#28) for participants at risk of gastrointestinal tract perforation per regulatory request; clarified use of sexual abstinence as contraceptive method only when consistent with preferred and usual participant lifestyle, per regulatory request; modified rater qualifications for Physician's Global Assessments to include healthcare professionals competent to perform the assessments; clarified expectation for pharmacokinetic sampling; included template language regarding protocol-specified serious adverse events.
03 October 2014	Clarified prohibited medications, per Brazil regulatory request; clarified rescue medication use prior to study visit per Brazil regulatory request; included updated Sponsor protocol template language.
01 February 2015	Additional contraceptive requirement was added for women of childbearing potential in Canada based upon Health Canada Guidance document; clarification of washout of prohibited medications was added, per Brazil regulatory request; language was updated for Adjudicated Safety Events and Safety Event Review Committees.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported